Colonoscopy just the start in preventing colorectal cancer

March 24, 2017, University of Connecticut
Dr. Joel Levine, right, heads the Colon Cancer Prevention Program at UConn Health, which focuses on identifying and managing risk. A clinical-translational program, its research findings have uncovered predictors of the development of polyps that can lead to colorectal cancer. Credit: Janine Gelineau/UConn Health Photo

When it comes to preventing colorectal cancer, there's a whole lot more to it than colonoscopy.

The understanding of how this cancer and the polyps that come before it develop is changing rapidly, says Dr. Joel Levine, co-founding director of UConn Health's Colon Cancer Prevention Program.

That's not to say the colonoscopy is no longer an important test. In fact, quite the opposite – it's become more of the starting point from which Levine's program derives a larger screening and prevention plan.

Advances in the interpretation of the colonoscopy's clinical findings are part of it. Combine that with an ultrasensitive blood stool test, and a targeted focus on the reduction of .

"The modifiable risk factors that we identify in this program, and reduce in a number of ways, reflect the translation of what's new in science to what we apply to the thousands of people we follow clinically," Levine says. "The key is the interaction of three broad areas: insulin biology, inflammation biology, and the billions of species of bacteria in the colon, the microbiome."

Insulin biology refers to anything that increases insulin levels, insulin-related proteins, or insulin resistance. These are risk factors, such as diabetes, being overweight, and lack of exercise, that often are referred to collectively as metabolic syndrome.

Second is cellular inflammation. It's a process that is not really visible to the patient, and this carries its own set of problems.

"If there's a lot of inflammatory signaling, sooner or later there's damage to genes, to DNA, to other elements in the cell," Levine says. "There are greater numbers of mutations, and sooner or later those mutations take hold and colon polyps develop, with their own natural history."

Inflammation often is a sign of a shift in the bacteria in the colon.

"That change in pattern induces a recognition on the part of the sensing cells in the colon, and the previously tolerant immune inflammatory pathways become intolerant, and the inflammatory activity markedly increases," Levine says.

He notes that changes in the microbiome are associated with specific outcomes, including : "You can associate specific patterns of bacterial change among the billions of species and the risk for colon cancer. Further evidence has demonstrated a relationship between specific bacteria and specific molecular pathways for colon polyps."

Polyp Predictors

The colonoscopy recognizes most polyps. But a recognition of inflammation and bacterial changes can reveal warning signs before the polyps form. And knowledge of the lifestyle choices associated with metabolic syndrome could alter a would-be colon cancer patient's path altogether.

"Dr. Ethan Bortniker is very active in this area of risk," Levine says. "He is an expert at understanding how things integrate."

Bortniker is director of research at UConn Health. He is involved in several studies trying to identify the relationship between elements of lifestyle reflected in the . In one of them, he uses an imaging device to measure liver fat as a direct predictor of the development of colon polyps.

"Our Colon Cancer Prevention Program is designed to identify risk, and modulate risk," Levine says. "The first colonoscopy tells you how that risk is being expressed. And the more we know about the biology of the colon and the biology of polyp and cancer formation, the more we can interdict the process."

While the colonoscopy is important, so are the efforts to lower patients' risk profile between colonoscopies. The results are quantifiable.

"We have not seen a colon cancer in any of the patients we follow in this risk-identification, risk-reduction pathway over at least the past five years," Levine says. "We think if you apply current biology, you will impact substantially the generally slow-growing, slow-developing process of and cancer. In normal circumstances, that's a six- to 10-year interval for polyps to develop, and therefore if you follow people carefully and regularly over time, you can stay ahead of the curve."

Contributing to the Colon Cancer Prevention Program's success, Levine says, is that patients are taking an active role in their well-being. The no-show rate, historically high in the world of colonoscopy, is very low in his program.

"People are so invested in this program," Levine says. "It really is a model in service and detail. Rather than sitting in an exam room, wearing a johnny, uncomfortable and in a hurry to leave, the patients sit here in my office. They become integrated in what we do. They become very fastidious and very loyal. We explain it, and they go back and they say, 'Wow, this is old-fashioned medicine in a new-fashioned way.' And it works. Everybody gets with the program."

Examining Blood Protein

To get a better handle on changes at the molecular level in between colonoscopies, UConn Health uses a souped-up version of the fecal immunochemical test (FIT). It measures the protein in blood in the stool in billionths of a gram. Levine says there are maybe a half-dozen other places in the country that do that.

"We follow this not just as a screening test for colon , but as an interval test in the years between colonoscopies to try to identify earlier when polyps may reappear," he says. "The reason this is so important is that the alternate pathway – not the adenoma pathway which we thought was the only one in the past – doesn't always obey the rules with regard to how fast polyps will appear. What the risk factors are in a given polyp may suggest that there is a higher risk for malignant transformation."

Levine notes that his program recently reported to the American College of Gastroenterology its first findings on looking at 1,000 patients and seeing the value of detecting a positive FIT test when used in the interval way.

Further study of this supersensitive FIT may yield data that could lead to non-colonoscopic screening becoming more prominent.

"Colonoscopy has a real value," Levine says. "The value for us is, what does it tell us about individual risk and how do you go forward in lowering the risk? And what is increasingly clear is that the molecular profiling of different polyp pathways is really going to be key, and the linking of that to things like the microbiome change will be very informative. So it's going to be 'colonoscopy plus,' and then there are going to be subsets of people who do not need to be followed by .

"There are going to be a lot of noninvasive ways in the future, in low-risk people, just to make sure that nature is not being capricious."

Explore further: Technology advances help to prevent, lessen impact of colon cancer

Related Stories

Technology advances help to prevent, lessen impact of colon cancer

March 14, 2017
Approximately 140,000 people are diagnosed with colorectal cancer in the U.S. each year. March is Colorectal Cancer Awareness Month.

Keep colon cancer at bay

March 22, 2017
(HealthDay)—Colon cancer can be treated and cured if it's diagnosed early, and a colonoscopy is one of the best ways to detect the disease, a gastroenterologist says.

Family history of colon cancer calls for earlier screening

March 21, 2017
(HealthDay)—If you've got a family history of colon or rectal cancers, you probably need to start screening for these conditions before you turn 50, a cancer expert says.

Certain types of polyps may warrant keeping closer tabs on the colon

April 13, 2016
Being on the lookout for certain features of polyps may help physicians keep a closer eye on patients at risk for colorectal cancer.

Some low-income, uninsured patients aren't referred for colonoscopy

December 13, 2016
(HealthDay)—Many low-income and uninsured patients don't have a follow-up colonoscopy after abnormal results on a colon cancer screening test—even if they're in a "safety net" health program, a new study finds.

Polyp removal doesn't always signal raised colon cancer risk, study says

August 27, 2014
(HealthDay)—Doctors may be performing too many repeat colonoscopies on people who've had pre-cancerous polyps removed during an earlier colon cancer screening, a new Norwegian study suggests.

Recommended for you

Student develops microfluidics device to help scientists identify early genetic markers of cancer

October 16, 2018
As anyone who has played "Where's Waldo" knows, searching for a single item in a landscape filled with a mélange of characters and objects can be a challenge. Chrissy O'Keefe, a Ph.D. student in the Department of Biomedical ...

A bad influence—the interplay between tumor cells and immune cells

October 16, 2018
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ...

Technique to 'listen' to a patient's brain during tumour surgery

October 16, 2018
Surgeons could soon eavesdrop on a patient's brain activity during surgery to remove their brain tumour, helping improve the accuracy of the operation and reduce the risk of impairing brain function.

Researchers elucidate roles of TP63 and SOX2 in squamous cell cancer progression

October 16, 2018
Squamous cell carcinomas (SCCs) are aggressive malignancies arising from the squamous epithelium of various organs, such as the esophagus, head and neck, lungs, and skin. Previous studies have demonstrated that two master ...

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Delving where few others have gone, leukemia researchers open new path

October 15, 2018
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.